Hidehito HORINOUCHI· @HHorinouchi · X·· 3 天前评分70
正文 · 原文
🔥OptiTROP-Lung06: Sac-TMT + pembrolizumab vs chemo + pembrolizumab in PD-L1-negative advanced NSCLC
🆙 @NEJM #ESMO26
☑Phase 3 RCT; N=455; PD-L1<1% nonsquamous NSCLC; mFU 9.7 mo
🎯mPFS 15.0 vs 5.7 mo (HR 0.49, p<0.001); mOS HR 0.58; grade ≥3 AEs lower with sac-TMT (47.6% vs 60.6%)
🎙Dr. Fei Zhou & Dr. Caicun Zhou
#LCSM @OncoAlert @Larvol @IASLC
https://www.nejm.org/doi/full/10.1056/NEJMoa2611280
74 浏览 · 3 赞 · 2 转发 · 0 回复
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung06: Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab (P) Versus Chemotherapy (Chemo) Plus Pembrolizumab (P) as First-Line (1L) Treatment for PD-L1-Negative Advanced Non-Squamous (Nsq) NSCLC: Randomized Phase 3 Study 🎙️Dr. Caicun Zhou 🔢LBA66 🎯Met Primary Endpoint: BICR-PFS 15.0 vs 5.7mo (HR 0.49, p<0.0001; n=455) 🎯OS Immature, Favorable Trend (HR 0.58) 🎯Grade≥3 TEAEs 47.6% vs 60.6%; Grade≥3 Stomatitis 2.2% ☑️NCT06711900 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/272 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com